- Trials with a EudraCT protocol (2)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
2 result(s) found for: Protein serine threonine kinase.
Displaying page 1 of 1.
EudraCT Number: 2011-006009-85 | Sponsor Protocol Number: 1 | Start Date*: 2012-06-04 |
Sponsor Name:VU University medical center | ||
Full Title: Prediction of response to kinase inhibitors based on protein phosphorylation profiles in tumor tissue from advanced renal cell cancer patients | ||
Medical condition: Advanced solid tumors | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-000185-22 | Sponsor Protocol Number: 20110265 | Start Date*: 2014-12-03 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: A Phase 1b/2, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With MK-3475 for Treatment of Previously Untreated, Unresected, Stage IIIB to IVM1c Melanoma | |||||||||||||
Medical condition: Previously Untreated, Unresected, Stage IIIB to IVM1c Melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) ES (Prematurely Ended) BE (Completed) DE (Prematurely Ended) AT (Prematurely Ended) GR (Completed) IT (Prematurely Ended) FI (Prematurely Ended) CZ (Completed) PT (Completed) HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
